Molecular Oncology Diagnostics Market by Product Type (Instruments, Reagents & Kits, Software & Services), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Microarray), Cancer Type, Sample Type, Application, End User - Global Forecast
Description
The Molecular Oncology Diagnostics Market was valued at USD 1.74 billion in 2024 and is projected to grow to USD 2.23 billion in 2025, with a CAGR of 29.85%, reaching USD 14.11 billion by 2032.
Contextual introduction to the evolving molecular oncology diagnostics landscape that frames clinical, technological, and commercial priorities for decision-makers
Molecular oncology diagnostics now sit at the intersection of rapid technological progress and evolving clinical imperatives, creating new opportunities and responsibilities for healthcare stakeholders. Advances in high-throughput sequencing, refined bioinformatics, and streamlined laboratory workflows have expanded the types of clinically actionable genomic information available to oncologists, pathologists, and translational researchers. At the same time, regulatory pathways and reimbursement landscapes continue to adapt, prompting diagnostic developers and providers to align evidence generation with payer and clinician expectations.
The diagnostic ecosystem is becoming more vertically integrated, with instrumentation, reagents, and informatics converging to deliver end-to-end solutions that support precision oncology pathways. This dynamic fosters collaboration between diagnostic laboratories, hospitals, pharmaceutical developers, and academic centers, while also intensifying competition among platform providers. As a result, organizations must recalibrate internal capabilities across sample handling, assay validation, data governance, and clinical reporting to maintain relevance and clinical trust.
Against this backdrop, leaders must balance near-term operational priorities with long-horizon investments in scalable technologies and data strategies. The following sections unpack transformative shifts in the landscape, regulatory and trade influences, segmentation-specific insights, and regional dynamics that collectively shape strategic decisions in molecular oncology diagnostics.
Detailed exploration of the major structural and technological shifts reshaping precision oncology diagnostics, clinical utility expectations, and commercial partnerships
The molecular oncology diagnostics field is undergoing several transformative shifts that are redefining how cancer is detected, characterized, and managed. First, an acceleration in sequencing depth and affordability has broadened the clinical utility of assays beyond single-gene tests toward multi-gene panels and comprehensive profiling, enabling richer molecular portraits of tumors that guide targeted therapies. Concurrently, liquid biopsy approaches are maturing, offering less invasive sampling and longitudinal monitoring capabilities that are reshaping surveillance and therapeutic response assessment.
Second, the integration of advanced informatics, artificial intelligence, and cloud-based data platforms is driving improvements in variant interpretation, clinical decision support, and interoperability across care settings. These tools are helping laboratories convert raw genomic data into clinically meaningful reports more consistently, while also enabling aggregation of real-world evidence for comparative effectiveness and regulatory submissions. Third, partnerships between diagnostic developers and pharmaceutical companies are intensifying, particularly around companion diagnostics and trial-enabling assays that tailor drug development to molecularly defined cohorts.
Finally, patient-centric care models and payer scrutiny are influencing evidence generation strategies, pushing stakeholders to demonstrate clinical utility through prospective studies and health-economic analyses. Together, these shifts require organizations to adopt flexible commercial models, invest in quality systems, and foster cross-functional expertise to translate technological capability into clinical impact.
Assessment of how evolving tariff policies can reshape procurement strategies, supply chain resilience, and capital purchasing decisions across diagnostic stakeholders
Tariff policies and trade measures in the United States have the potential to affect procurement, sourcing strategies, and cost structures within the molecular oncology diagnostics supply chain. Changes to tariff classifications or the imposition of duties on laboratory instruments, reagents, or imported components can disrupt established supplier relationships and prompt procurement teams to diversify vendors or accelerate local sourcing initiatives. In turn, manufacturers and distributors may reassess manufacturing footprints, contract terms, and inventory strategies to mitigate operational exposure.
Moreover, tariffs can influence the cadence of capital equipment purchases by clinical laboratories and hospitals, as procurement cycles often factor in total landed cost and availability of service agreements. Diagnostic companies that rely on global supply chains may face increased complexity in pricing and contracting, requiring transparent communication with customers and flexible commercial models to preserve adoption momentum. In addition, research institutions that import specialized consumables could adjust experimental timelines or seek substitutions, which may affect collaborative trials and translational programs.
In response to evolving tariff dynamics, stakeholders are advised to conduct scenario planning that evaluates supplier resilience, alternative logistics options, and contractual protections. This adaptive posture enables organizations to maintain continuity of care and research while navigating policy-driven cost pressures and supply chain uncertainty.
Comprehensive segmentation insights integrating product, technology, test type, application, cancer type, end user, and sample type drivers that inform strategic prioritization
Understanding the market requires a granular view across product, technology, test type, application, cancer type, end user, and sample type segments to identify where clinical demand and operational complexity converge. From a product perspective, instruments, reagents and kits, and software and services form interdependent value streams; instruments enable assay performance, reagents and kits standardize analytical workflows, and software and services deliver interpretation, reporting, and lab operations management. Technology segmentation spans fluorescence in situ hybridization, immunohistochemistry, microarray, next generation sequencing, and real time PCR, with next generation sequencing further differentiated into targeted sequencing, whole exome sequencing, and whole genome sequencing, and targeted sequencing subdivided into comprehensive panel and hotspot panel approaches that vary in breadth and clinical intent.
Test types are evolving in parallel, with liquid biopsy, multi-gene panel testing, single gene testing, whole exome sequencing, and whole genome sequencing each addressing distinct clinical use cases-from minimally invasive monitoring to deep genomic characterization. Application-driven demand includes companion diagnostics, early detection, personalized medicine, prognosis and monitoring, and research use, and these applications guide assay design, validation depth, and regulatory strategy. Cancer type differentiation-such as breast, colorectal, leukemia, lung, and prostate cancers-shapes biomarker prevalence, testing algorithms, and therapeutic linkage, while end users including diagnostic laboratories, hospitals and clinics, pharmaceutical and biotech companies, and research institutes exhibit unique procurement, quality, and turnaround requirements. Finally, sample type considerations across plasma-based, saliva and urine, tissue-based, and whole blood samples influence pre-analytical workflows, assay sensitivity, and clinical adoption patterns.
Synthesizing these segmentation layers reveals where value accrues and where operational friction persists, enabling stakeholders to prioritize investments in platforms, companion assays, or data services that align with clinical demand and laboratory capabilities.
Regional strategic analysis highlighting how geographic differences in regulation, clinical practice, and capacity shape diagnostic adoption and commercial approaches
Regional dynamics are a critical determinant of adoption pathways, regulatory expectations, and commercial models across the molecular oncology diagnostics landscape. In the Americas, clinical laboratories and integrated health systems frequently drive early adoption of sequencing-based assays and liquid biopsy monitoring, supported by established reimbursement frameworks and a dense ecosystem of clinical trials. In contrast, Europe's regulatory environment emphasizes harmonization and clinical evidence, prompting diagnostic developers to tailor validation strategies and engage with reference laboratories to demonstrate clinical utility across national health systems. The Middle East and Africa present heterogeneous readiness levels, with pockets of advanced diagnostic hubs and broader capacity constraints that influence local deployment models.
Asia-Pacific markets display wide variability, combining high-volume manufacturing capabilities with rapidly expanding clinical infrastructure. Several countries in the region are accelerating adoption of next generation sequencing and liquid biopsy through national screening initiatives and investment in precision medicine programs, while others continue to strengthen laboratory accreditation and training. These geographic variations influence commercial tactics: in some regions, partnerships with local distributors and laboratory networks accelerate access, whereas in others, centralized reference lab models or public-private collaborations prove more effective.
Taken together, regional insights underscore the importance of adaptable commercialization strategies, regulatory foresight, and capacity-building initiatives to ensure equitable access to high-quality molecular oncology diagnostics across diverse health systems.
Insightful company-level analysis describing strategic positioning, partnership models, and commercialization approaches that drive competitive differentiation in diagnostics
Leading companies in the molecular oncology diagnostics ecosystem are advancing differentiated strategies that combine platform innovation, assay portfolios, and services designed to reduce time-to-insight and increase clinical actionability. Some firms focus on high-throughput sequencing platforms coupled with informatics suites to deliver integrated solutions for large clinical laboratories and reference centers, while others prioritize modular or targeted approaches that meet the needs of decentralized hospital labs and specialty oncology clinics. Strategic collaborations between diagnostic companies and pharmaceutical developers have become central to accelerating companion diagnostic development and ensuring alignment with therapeutic pipelines.
Beyond technology, successful organizations invest in regulatory expertise, clinical validation programs, and payer engagement to build durable market access. Many also expand their offering into data services and real-world evidence generation to support label expansions and health-economic narratives. At the same time, business models are diversifying: subscription-based informatics, reagent-as-a-service arrangements, and managed testing services are gaining traction as customers seek predictable costs and simplified operational workflows. These strategic choices reflect a broader trend toward delivering outcomes rather than just products, with companies positioning themselves as partners in clinical decision-making and trial enablement.
Actionable recommendations for diagnostic developers, laboratories, and commercial teams to enhance evidence generation, supply chain resilience, and patient-centric service delivery
Industry leaders can take concrete steps to strengthen clinical relevance, supply chain resilience, and commercial durability in the molecular oncology diagnostics domain. First, prioritize investments in robust evidence-generation frameworks that align analytical validation with prospective clinical studies and payer-relevant endpoints. This reduces friction during reimbursement discussions and supports wider clinical adoption. Second, diversify supply chains and localize critical component sourcing where feasible to mitigate exposure to trade disruptions and tariffs, while also negotiating flexible service and pricing terms to protect customers from cost volatility.
Third, build interoperable informatics and reporting platforms that facilitate seamless integration with electronic health records and clinical workflows; this enhances user adoption and enables the aggregation of real-world data for iterative product improvement. Fourth, adopt customer-centric commercialization models that offer flexible licensing, managed services, or bundled solutions tuned to laboratory scale and clinical use cases. Fifth, pursue targeted partnerships with pharmaceutical companies and academic centers to co-develop companion diagnostics and support biomarker-driven trials, thereby strengthening clinical linkage and market pull. Finally, invest in workforce training, accreditation support, and quality systems for decentralized testing environments to ensure consistent assay performance across diverse end users.
Taken together, these actions will help organizations translate technological capability into sustained clinical impact and commercial resilience.
Transparent description of the multi-method research approach combining primary interviews, secondary literature review, and scenario analysis to ensure robust findings
The underlying research methodology combines multi-source evidence gathering and expert validation to produce a balanced and actionable analysis. Primary research includes structured interviews with clinical laboratory directors, hospital procurement leaders, regulatory specialists, and industry executives to capture operational realities, adoption barriers, and strategic priorities. Secondary research synthesizes peer-reviewed literature, clinical guidelines, regulatory filings, and publicly available product documentation to contextualize technological capabilities and clinical use cases. Where applicable, policy announcements and trade notices are reviewed to assess potential operational impacts.
Analytical approaches include qualitative thematic synthesis and cross-validation of expert insights to identify recurring trends and divergence points. Scenario analysis is used to explore supply chain and policy sensitivities, while technology mapping clarifies where assay performance, throughput, and informatics converge to meet clinical needs. To ensure rigor, findings are triangulated across sources and reviewed by independent domain specialists with clinical and laboratory expertise. This methodological rigor underpins the report’s strategic recommendations and supports confident translation into organizational decision-making.
Concise conclusion synthesizing how technological, regulatory, and commercial dynamics converge to shape the future of precision oncology diagnostics
In conclusion, molecular oncology diagnostics are advancing along multiple, converging trajectories that collectively elevate the potential for precision cancer care. Technological maturation in sequencing and liquid biopsy, together with improved informatics and growing collaboration between diagnostics and therapeutics developers, is expanding clinically actionable opportunities. At the same time, regulatory evolution, regional variability, and trade dynamics introduce complexity that organizations must proactively manage through evidence alignment, supply chain strategy, and adaptable commercial models.
Leaders who integrate rigorous clinical validation, interoperable data platforms, and customer-centric service models will position themselves to translate diagnostic innovation into measurable clinical benefits. Moreover, by investing in partnerships with pharmaceutical companies, academic centers, and regional laboratory networks, organizations can accelerate adoption while sharing the evidentiary burden. Ultimately, the path forward requires disciplined execution, continuous learning from real-world outcomes, and an unwavering focus on patient-centered value.
Note: PDF & Excel + Online Access - 1 Year
Contextual introduction to the evolving molecular oncology diagnostics landscape that frames clinical, technological, and commercial priorities for decision-makers
Molecular oncology diagnostics now sit at the intersection of rapid technological progress and evolving clinical imperatives, creating new opportunities and responsibilities for healthcare stakeholders. Advances in high-throughput sequencing, refined bioinformatics, and streamlined laboratory workflows have expanded the types of clinically actionable genomic information available to oncologists, pathologists, and translational researchers. At the same time, regulatory pathways and reimbursement landscapes continue to adapt, prompting diagnostic developers and providers to align evidence generation with payer and clinician expectations.
The diagnostic ecosystem is becoming more vertically integrated, with instrumentation, reagents, and informatics converging to deliver end-to-end solutions that support precision oncology pathways. This dynamic fosters collaboration between diagnostic laboratories, hospitals, pharmaceutical developers, and academic centers, while also intensifying competition among platform providers. As a result, organizations must recalibrate internal capabilities across sample handling, assay validation, data governance, and clinical reporting to maintain relevance and clinical trust.
Against this backdrop, leaders must balance near-term operational priorities with long-horizon investments in scalable technologies and data strategies. The following sections unpack transformative shifts in the landscape, regulatory and trade influences, segmentation-specific insights, and regional dynamics that collectively shape strategic decisions in molecular oncology diagnostics.
Detailed exploration of the major structural and technological shifts reshaping precision oncology diagnostics, clinical utility expectations, and commercial partnerships
The molecular oncology diagnostics field is undergoing several transformative shifts that are redefining how cancer is detected, characterized, and managed. First, an acceleration in sequencing depth and affordability has broadened the clinical utility of assays beyond single-gene tests toward multi-gene panels and comprehensive profiling, enabling richer molecular portraits of tumors that guide targeted therapies. Concurrently, liquid biopsy approaches are maturing, offering less invasive sampling and longitudinal monitoring capabilities that are reshaping surveillance and therapeutic response assessment.
Second, the integration of advanced informatics, artificial intelligence, and cloud-based data platforms is driving improvements in variant interpretation, clinical decision support, and interoperability across care settings. These tools are helping laboratories convert raw genomic data into clinically meaningful reports more consistently, while also enabling aggregation of real-world evidence for comparative effectiveness and regulatory submissions. Third, partnerships between diagnostic developers and pharmaceutical companies are intensifying, particularly around companion diagnostics and trial-enabling assays that tailor drug development to molecularly defined cohorts.
Finally, patient-centric care models and payer scrutiny are influencing evidence generation strategies, pushing stakeholders to demonstrate clinical utility through prospective studies and health-economic analyses. Together, these shifts require organizations to adopt flexible commercial models, invest in quality systems, and foster cross-functional expertise to translate technological capability into clinical impact.
Assessment of how evolving tariff policies can reshape procurement strategies, supply chain resilience, and capital purchasing decisions across diagnostic stakeholders
Tariff policies and trade measures in the United States have the potential to affect procurement, sourcing strategies, and cost structures within the molecular oncology diagnostics supply chain. Changes to tariff classifications or the imposition of duties on laboratory instruments, reagents, or imported components can disrupt established supplier relationships and prompt procurement teams to diversify vendors or accelerate local sourcing initiatives. In turn, manufacturers and distributors may reassess manufacturing footprints, contract terms, and inventory strategies to mitigate operational exposure.
Moreover, tariffs can influence the cadence of capital equipment purchases by clinical laboratories and hospitals, as procurement cycles often factor in total landed cost and availability of service agreements. Diagnostic companies that rely on global supply chains may face increased complexity in pricing and contracting, requiring transparent communication with customers and flexible commercial models to preserve adoption momentum. In addition, research institutions that import specialized consumables could adjust experimental timelines or seek substitutions, which may affect collaborative trials and translational programs.
In response to evolving tariff dynamics, stakeholders are advised to conduct scenario planning that evaluates supplier resilience, alternative logistics options, and contractual protections. This adaptive posture enables organizations to maintain continuity of care and research while navigating policy-driven cost pressures and supply chain uncertainty.
Comprehensive segmentation insights integrating product, technology, test type, application, cancer type, end user, and sample type drivers that inform strategic prioritization
Understanding the market requires a granular view across product, technology, test type, application, cancer type, end user, and sample type segments to identify where clinical demand and operational complexity converge. From a product perspective, instruments, reagents and kits, and software and services form interdependent value streams; instruments enable assay performance, reagents and kits standardize analytical workflows, and software and services deliver interpretation, reporting, and lab operations management. Technology segmentation spans fluorescence in situ hybridization, immunohistochemistry, microarray, next generation sequencing, and real time PCR, with next generation sequencing further differentiated into targeted sequencing, whole exome sequencing, and whole genome sequencing, and targeted sequencing subdivided into comprehensive panel and hotspot panel approaches that vary in breadth and clinical intent.
Test types are evolving in parallel, with liquid biopsy, multi-gene panel testing, single gene testing, whole exome sequencing, and whole genome sequencing each addressing distinct clinical use cases-from minimally invasive monitoring to deep genomic characterization. Application-driven demand includes companion diagnostics, early detection, personalized medicine, prognosis and monitoring, and research use, and these applications guide assay design, validation depth, and regulatory strategy. Cancer type differentiation-such as breast, colorectal, leukemia, lung, and prostate cancers-shapes biomarker prevalence, testing algorithms, and therapeutic linkage, while end users including diagnostic laboratories, hospitals and clinics, pharmaceutical and biotech companies, and research institutes exhibit unique procurement, quality, and turnaround requirements. Finally, sample type considerations across plasma-based, saliva and urine, tissue-based, and whole blood samples influence pre-analytical workflows, assay sensitivity, and clinical adoption patterns.
Synthesizing these segmentation layers reveals where value accrues and where operational friction persists, enabling stakeholders to prioritize investments in platforms, companion assays, or data services that align with clinical demand and laboratory capabilities.
Regional strategic analysis highlighting how geographic differences in regulation, clinical practice, and capacity shape diagnostic adoption and commercial approaches
Regional dynamics are a critical determinant of adoption pathways, regulatory expectations, and commercial models across the molecular oncology diagnostics landscape. In the Americas, clinical laboratories and integrated health systems frequently drive early adoption of sequencing-based assays and liquid biopsy monitoring, supported by established reimbursement frameworks and a dense ecosystem of clinical trials. In contrast, Europe's regulatory environment emphasizes harmonization and clinical evidence, prompting diagnostic developers to tailor validation strategies and engage with reference laboratories to demonstrate clinical utility across national health systems. The Middle East and Africa present heterogeneous readiness levels, with pockets of advanced diagnostic hubs and broader capacity constraints that influence local deployment models.
Asia-Pacific markets display wide variability, combining high-volume manufacturing capabilities with rapidly expanding clinical infrastructure. Several countries in the region are accelerating adoption of next generation sequencing and liquid biopsy through national screening initiatives and investment in precision medicine programs, while others continue to strengthen laboratory accreditation and training. These geographic variations influence commercial tactics: in some regions, partnerships with local distributors and laboratory networks accelerate access, whereas in others, centralized reference lab models or public-private collaborations prove more effective.
Taken together, regional insights underscore the importance of adaptable commercialization strategies, regulatory foresight, and capacity-building initiatives to ensure equitable access to high-quality molecular oncology diagnostics across diverse health systems.
Insightful company-level analysis describing strategic positioning, partnership models, and commercialization approaches that drive competitive differentiation in diagnostics
Leading companies in the molecular oncology diagnostics ecosystem are advancing differentiated strategies that combine platform innovation, assay portfolios, and services designed to reduce time-to-insight and increase clinical actionability. Some firms focus on high-throughput sequencing platforms coupled with informatics suites to deliver integrated solutions for large clinical laboratories and reference centers, while others prioritize modular or targeted approaches that meet the needs of decentralized hospital labs and specialty oncology clinics. Strategic collaborations between diagnostic companies and pharmaceutical developers have become central to accelerating companion diagnostic development and ensuring alignment with therapeutic pipelines.
Beyond technology, successful organizations invest in regulatory expertise, clinical validation programs, and payer engagement to build durable market access. Many also expand their offering into data services and real-world evidence generation to support label expansions and health-economic narratives. At the same time, business models are diversifying: subscription-based informatics, reagent-as-a-service arrangements, and managed testing services are gaining traction as customers seek predictable costs and simplified operational workflows. These strategic choices reflect a broader trend toward delivering outcomes rather than just products, with companies positioning themselves as partners in clinical decision-making and trial enablement.
Actionable recommendations for diagnostic developers, laboratories, and commercial teams to enhance evidence generation, supply chain resilience, and patient-centric service delivery
Industry leaders can take concrete steps to strengthen clinical relevance, supply chain resilience, and commercial durability in the molecular oncology diagnostics domain. First, prioritize investments in robust evidence-generation frameworks that align analytical validation with prospective clinical studies and payer-relevant endpoints. This reduces friction during reimbursement discussions and supports wider clinical adoption. Second, diversify supply chains and localize critical component sourcing where feasible to mitigate exposure to trade disruptions and tariffs, while also negotiating flexible service and pricing terms to protect customers from cost volatility.
Third, build interoperable informatics and reporting platforms that facilitate seamless integration with electronic health records and clinical workflows; this enhances user adoption and enables the aggregation of real-world data for iterative product improvement. Fourth, adopt customer-centric commercialization models that offer flexible licensing, managed services, or bundled solutions tuned to laboratory scale and clinical use cases. Fifth, pursue targeted partnerships with pharmaceutical companies and academic centers to co-develop companion diagnostics and support biomarker-driven trials, thereby strengthening clinical linkage and market pull. Finally, invest in workforce training, accreditation support, and quality systems for decentralized testing environments to ensure consistent assay performance across diverse end users.
Taken together, these actions will help organizations translate technological capability into sustained clinical impact and commercial resilience.
Transparent description of the multi-method research approach combining primary interviews, secondary literature review, and scenario analysis to ensure robust findings
The underlying research methodology combines multi-source evidence gathering and expert validation to produce a balanced and actionable analysis. Primary research includes structured interviews with clinical laboratory directors, hospital procurement leaders, regulatory specialists, and industry executives to capture operational realities, adoption barriers, and strategic priorities. Secondary research synthesizes peer-reviewed literature, clinical guidelines, regulatory filings, and publicly available product documentation to contextualize technological capabilities and clinical use cases. Where applicable, policy announcements and trade notices are reviewed to assess potential operational impacts.
Analytical approaches include qualitative thematic synthesis and cross-validation of expert insights to identify recurring trends and divergence points. Scenario analysis is used to explore supply chain and policy sensitivities, while technology mapping clarifies where assay performance, throughput, and informatics converge to meet clinical needs. To ensure rigor, findings are triangulated across sources and reviewed by independent domain specialists with clinical and laboratory expertise. This methodological rigor underpins the report’s strategic recommendations and supports confident translation into organizational decision-making.
Concise conclusion synthesizing how technological, regulatory, and commercial dynamics converge to shape the future of precision oncology diagnostics
In conclusion, molecular oncology diagnostics are advancing along multiple, converging trajectories that collectively elevate the potential for precision cancer care. Technological maturation in sequencing and liquid biopsy, together with improved informatics and growing collaboration between diagnostics and therapeutics developers, is expanding clinically actionable opportunities. At the same time, regulatory evolution, regional variability, and trade dynamics introduce complexity that organizations must proactively manage through evidence alignment, supply chain strategy, and adaptable commercial models.
Leaders who integrate rigorous clinical validation, interoperable data platforms, and customer-centric service models will position themselves to translate diagnostic innovation into measurable clinical benefits. Moreover, by investing in partnerships with pharmaceutical companies, academic centers, and regional laboratory networks, organizations can accelerate adoption while sharing the evidentiary burden. Ultimately, the path forward requires disciplined execution, continuous learning from real-world outcomes, and an unwavering focus on patient-centered value.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI-driven bioinformatics platforms for complex tumor profiling and targeted therapy selection
- 5.2. Emergence of CRISPR-based liquid biopsy diagnostics for real-time monitoring of minimal residual disease in oncology
- 5.3. Expansion of multi-omics assays integrating genomics, transcriptomics, and proteomics for personalized oncology diagnosis
- 5.4. Rising adoption of next-generation sequencing panels targeting actionable cancer biomarkers in clinical practice
- 5.5. Development of digital pathology and AI-powered image analysis tools for more accurate molecular oncology diagnostics
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Molecular Oncology Diagnostics Market, by Product Type
- 8.1. Instruments
- 8.2. Reagents & Kits
- 8.3. Software & Services
- 9. Molecular Oncology Diagnostics Market, by Technology
- 9.1. Fluorescence In Situ Hybridization
- 9.2. Immunohistochemistry
- 9.3. Microarray
- 9.4. Next Generation Sequencing
- 9.4.1. Targeted Sequencing
- 9.4.1.1. Comprehensive Panel
- 9.4.1.2. Hotspot Panel
- 9.4.2. Whole Exome Sequencing
- 9.4.3. Whole Genome Sequencing
- 9.5. Real Time PCR
- 10. Molecular Oncology Diagnostics Market, by Cancer Type
- 10.1. Breast Cancer
- 10.2. Colorectal Cancer
- 10.3. Leukemia
- 10.4. Lung Cancer
- 10.5. Prostate Cancer
- 11. Molecular Oncology Diagnostics Market, by Sample Type
- 11.1. Plasma Based
- 11.2. Saliva & Urine
- 11.3. Tissue Based
- 11.4. Whole Blood
- 12. Molecular Oncology Diagnostics Market, by Application
- 12.1. Companion Diagnostics
- 12.2. Early Detection
- 12.3. Personalized Medicine
- 12.4. Prognosis & Monitoring
- 12.5. Research Use
- 13. Molecular Oncology Diagnostics Market, by End User
- 13.1. Diagnostic Laboratories
- 13.2. Hospitals & Clinics
- 13.3. Pharmaceutical & Biotech Companies
- 13.4. Research Institutes
- 14. Molecular Oncology Diagnostics Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Molecular Oncology Diagnostics Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Molecular Oncology Diagnostics Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Abbott Laboratories
- 17.3.2. Agilent Technologies, Inc.
- 17.3.3. Bayer AG
- 17.3.4. Becton, Dickinson and Company
- 17.3.5. Bio-Rad Laboratories, Inc.
- 17.3.6. Biocartis NV
- 17.3.7. Biocept, Inc.
- 17.3.8. BIOMÉRIEUX SA
- 17.3.9. Danaher Corporation
- 17.3.10. DiaSorin Molecular LLC
- 17.3.11. Enzo Biochem, Inc.
- 17.3.12. Exact Sciences Corporation
- 17.3.13. F. Hoffmann-La Roche Ltd
- 17.3.14. GenMark Saglik
- 17.3.15. Guardant Health, Inc.
- 17.3.16. Hologic, Inc.
- 17.3.17. Illumina Inc.
- 17.3.18. Leica Biosystems Nussloch GmbH
- 17.3.19. Myriad Genetics, Inc.
- 17.3.20. NeoGenomics Laboratories
- 17.3.21. OncoCyte Corporation
- 17.3.22. PathAI, Inc.
- 17.3.23. Personal Genome Diagnostics Inc.
- 17.3.24. QIAGEN N.V.
- 17.3.25. Siemens AG
- 17.3.26. Sysmex Asia Pacific Pte Ltd.
- 17.3.27. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
